Cat. No.: HY-N0828

Pterostilbene

11 Cited Publications

Avis client

Based on 11 publication(s) in Google Scholar

Pterostilbene is a stilbenoid isolated from blueberries and Pterocarpus marsupium. Shows anti-oxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and anti-obesity properties. Pterostilbene blocks ROS production, also exhibits inhibitory activity against various free radicals such as DPPH, ABTS, hydroxyl, superoxide and hydrogen peroxide.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.89%
CAS No.: 537-42-8
Formule: C₁₆H₁₆O₃
Masse moléculaire:256.30

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Pterostilbene Chemical Structure

CAS No.: 537-42-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (11)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Pterostilbene is a stilbenoid isolated from blueberries and Pterocarpus marsupium^[1]. Shows anti-oxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and anti-obesity properties^[1]^[4]. Pterostilbene blocks ROS production^[3], also exhibits inhibitory activity against various free radicals such as DPPH, ABTS, hydroxyl, superoxide and hydrogen peroxide^[4].

Cellular Effect

Cell Line	Type	Value	Description	References
518A2	IC₅₀	17.39 μM Compound: 21	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 22749392]
518A2	IC₅₀	17.39 μmol Compound: 21	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 22749392]
A253 cell line	IC₅₀	17.33 μM Compound: 21	Cytotoxicity against human A253 cells after 96 hrs by SRB assay Cytotoxicity against human A253 cells after 96 hrs by SRB assay	[PMID: 22749392]
A253 cell line	IC₅₀	17.33 μmol Compound: 21	Cytotoxicity against human A253 cells after 96 hrs by SRB assay Cytotoxicity against human A253 cells after 96 hrs by SRB assay	[PMID: 22749392]
A2780	IC₅₀	15.56 μM Compound: 21	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 22749392]
A2780	IC₅₀	15.56 μmol Compound: 21	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 22749392]
A549	IC₅₀	71.7 μM Compound: 6	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19689125]
A549	IC₅₀	15.86 μM Compound: 21	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 22749392]
A549	IC₅₀	15.86 μmol Compound: 21	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 22749392]
A549	IC₅₀	26 μM Compound: Pter	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
B16-BL6	IC₅₀	15.9 μM Compound: 6	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 19689125]
BXPC-3	GI₅₀	6.5 μg/mL Compound: 14d	In vitro growth inhibition of BXPC-3 (human pancreatic adenocarcinoma) cell line. In vitro growth inhibition of BXPC-3 (human pancreatic adenocarcinoma) cell line.	[PMID: 12036362]
BXPC-3	IC₅₀	31 μM Compound: Pter	Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
Caco-2	IC₅₀	14.46 μM Compound: 16, Pterostilbene	Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
COLO 201	IC₅₀	29 μM Compound: Pter	Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
DLD-1	IC₅₀	16.45 μM Compound: 21	Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay	[PMID: 22749392]
DLD-1	IC₅₀	16.45 μmol Compound: 21	Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay	[PMID: 22749392]
DU-145	GI₅₀	2.7 μg/mL Compound: 14d	In vitro growth inhibition of DU-145 (human prostate carcinoma) cell line. In vitro growth inhibition of DU-145 (human prostate carcinoma) cell line.	[PMID: 12036362]
DU-145	GI₅₀	4.3 μg/mL Compound: 14d	The concentration causing 50% reduction in the net protein increase (cell growth inhibition, GI50) against central nervous system (CNS) SF-268 cells The concentration causing 50% reduction in the net protein increase (cell growth inhibition, GI50) against central nervous system (CNS) SF-268 cells	[PMID: 12036362]
HCT-116	IC₅₀	>60 μM Compound: 2	Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
HCT-116	IC₅₀	34.08 μM Compound: PTE	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34043359]
HCT-116	IC₅₀	34.08 μM Compound: PTE	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 38964169]
HEK293	IC₅₀	19.5 μM Compound: 1H6	Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay	[PMID: 18487053]
HEK293	EC₅₀	3.6 μM Compound: 7	Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level	[PMID: 26750258]
HEK293	IC₅₀	>10 μM Compound: 7	Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level	[PMID: 26750258]
HEK293	IC₅₀	7.5 μM Compound: 7	Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level	[PMID: 26750258]
HeLa	IC₅₀	9.43 μM Compound: 6	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19689125]
HL-60	IC₅₀	35 μM Compound: 12a	In vitro inhibitory concentration against proliferation of HL60 cells In vitro inhibitory concentration against proliferation of HL60 cells	[PMID: 12877593]
HL-60	IC₅₀	35 μM Compound: 2a, pterostilbene	Antiproliferative activity against human HL60 cell line Antiproliferative activity against human HL60 cell line	[PMID: 16686543]
HT-1080	IC₅₀	93.4 μM Compound: 6	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 19689125]
HT-29	IC₅₀	23.8 μM Compound: 16, Pterostilbene	Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
HT-29	IC₅₀	>60 μM Compound: 2	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
HT-29	IC₅₀	28 μM Compound: Pter	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
J774	IC₅₀	10.5 μM Compound: 4	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA	[PMID: 29726680]
J774	IC₅₀	16.7 μM Compound: 4	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 29726680]
J774	IC₅₀	8.7 μM Compound: 4	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA	[PMID: 29726680]
K562	IC₅₀	10 μM Compound: 2a, pterostilbene	Antiproliferative activity against human K562 cell line expressing Bcr-Abl Antiproliferative activity against human K562 cell line expressing Bcr-Abl	[PMID: 16686543]
KM-20L2	GI₅₀	3.4 μg/mL Compound: 14d	In vitro growth inhibition of KM20L2 cell line. In vitro growth inhibition of KM20L2 cell line.	[PMID: 12036362]
L02	IC₅₀	>100 μM Compound: Pter	Cytotoxicity against human L-02 cells incubated for 24 hrs by MTT assay Cytotoxicity against human L-02 cells incubated for 24 hrs by MTT assay	[PMID: 34506712]
LN-229	IC₅₀	14 μM Compound: Pter	Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MCF7	GI₅₀	2.3 μg/mL Compound: 14d	Cell growth inhibition of breast MCF-7 cells, expressed as 50% reduction in the net protein increase Cell growth inhibition of breast MCF-7 cells, expressed as 50% reduction in the net protein increase	[PMID: 12036362]
MCF7	IC₅₀	14.11 μM Compound: 21	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 22749392]
MCF7	IC₅₀	14.11 μmol Compound: 21	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 22749392]
MCF7	IC₅₀	65 μM Compound: Pterostlibene	Cytotoxicity against human MCF7 cells measured 24 hrs by MTT assay Cytotoxicity against human MCF7 cells measured 24 hrs by MTT assay	[PMID: 27598238]
MDA-MB-231	IC₅₀	10 μM Compound: 2	Inhibitory concentration required for antiproliferative activity against human MDA-MB-231 cells Inhibitory concentration required for antiproliferative activity against human MDA-MB-231 cells	[PMID: 16250636]
MDA-MB-231	IC₅₀	63 μM Compound: Pter	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MDA-MB-231	IC₅₀	31.17 μM Compound: PTE	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34043359]
MDA-MB-231	IC₅₀	31.17 μM Compound: PTE	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 38964169]
MDR	IC₅₀	42 μM Compound: 2a, pterostilbene	Antiproliferative activity against MDR human HL60R cell line Antiproliferative activity against MDR human HL60R cell line	[PMID: 16686543]
NCI-H460	GI₅₀	2.7 μg/mL Compound: 14d	In vitro growth inhibition of NCI-H460 (human non-small cell lung carcinoma) cell line. In vitro growth inhibition of NCI-H460 (human non-small cell lung carcinoma) cell line.	[PMID: 12036362]
NCI-H460	IC₅₀	17 μM Compound: Pter	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
NIH3T3	IC₅₀	12.2 μM Compound: 16	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B colorimetric assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B colorimetric assay	[PMID: 21803587]
NIH3T3	IC₅₀	12.19 μM Compound: 21	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 22749392]
NIH3T3	IC₅₀	12.19 μmol Compound: 21	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 22749392]
P388	ED₅₀	4.87 μg/mL Compound: 14d	In vitro inhibition of P388 (murine leukemia) cell proliferation. In vitro inhibition of P388 (murine leukemia) cell proliferation.	[PMID: 12036362]
PANC-1	IC₅₀	50 μM Compound: Pter	Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
RAW264.7	IC₅₀	30 μM Compound: 1b	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay	[PMID: 31350127]
SK-MEL-2	IC₅₀	17 μM Compound: Pter	Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
T47D	IC₅₀	35 μM Compound: Pter	Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
U-87MG ATCC	IC₅₀	34 μM Compound: Pter	Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]

In Vitro

Pterostilbene (0, 5, 25, 50, 100, 200 and 400 μM) shows inhibitory activity against the growth of HeLa cells, with IC₅₀s of 101.2 μM and 65.9 μM at 24 and 48 hrs, respectively. Ipterostilbene (0, 25, 100 and 200 μM) also induces the apoptosis HeLa cells^[2].
Pterostilbene (0.05, 0.1, 0.15 and 0.2 mM) has high anti-oxidant activity against DPPH, ABTS, hydroxyl, superoxide, hydrogen peroxide in a dose-dependent manner. Pterostilbene decreases lipid peroxides and hydroperoxides, reduces protein carbonyl groups and restores protein sulphydryl groups in response to damage by TBHP and As-Fe²⁺. Pterostilbene also inhibits single strand breaks in pBR322^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pterostilbene (30 mg/kg daily, p.o. for 21 days) inhibits reactive oxygen species production in the animal model of inflammation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 537-42-8
Appearance Solid
Masse moléculaire 256.30
Formule C₁₆H₁₆O₃
Color White to off-white
SMILES

OC1=CC=C(/C=C/C2=CC(OC)=CC(OC)=C2)C=C1
Structure Classification
- Phenols
- Monophenols
- Stilbenes
Initial Source
- Plants
- other families
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (11)

All Cell Imaging/StainingRT-PCRWBIFIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Redox Biol

Gaylussacin, a stilbene glycoside, inhibits chronic obstructive pulmonary disease in mice. [Abstract]

2025 Jun 26:85:103744. PMID: 40614364
Phytomedicine

Bruceantin inhibits the c-Myc/RL27A axis to suppress tumor progression in hepatocellular carcinoma. [Abstract]

2025 Dec 24:150:157740. PMID: 41477978
J Clean Prod

2023 Mar 28.
Phytother Res

Pterostilbene Exhibits Broad-Spectrum Antiviral Activity by Targeting the Enterovirus Capsid, Inactivating Viral Particles, Blocking Viral Binding, and Protecting Mice From Lethal EV-A71 Challenge. [Abstract]

2025 Apr 16. PMID: 40235439

Pterostilbene purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Apr 16. [Abstract]

Cell morphology of EV-A71- and EV-D68-infected cells treated with Pterostilbene (Pte) (20 and 40 μM; 48 h) or Resveratrol (Res) under a phase-contrast microscope. Pterostilbene (Pte) treatment was significantly better than Resveratrol (Res) in protecting RD cells from EV-A71 and EV-D68 infection.

Pterostilbene purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Apr 16. [Abstract]

RD cells were infected with EV-A71 or EV-D68 at an MOI of 0.1 for 1 h, and then cells were treated with Pterostilbene (Pte) (10-40 μM; 24 h). The levels of viral RNA were quantified using RT-PCR.

Pterostilbene purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Apr 16. [Abstract]

The protein levels of VP1 were detected using western blot analysis. RD cells were infected with EV-A71 at an MOI of 0.1, 0.2, and 0.5 for 1 h, and then the cells were treated with Pterostilbene (Pte) (20 μM; 24 h). Pterostilbene (Pte) treatment downregulated the levels of VP1 protein.

Pterostilbene purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Apr 16. [Abstract]

RD cells were mock-infected or infected with EV-A71 at a MOI of 0.1 for 1 h, and then cells were treated with Pterostilbene (Pte) (5-20 μM; 24 h). Pterostilbene (Pte) reduced synthesis of VP1 protein for EV-A71.

Pterostilbene purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Apr 16. [Abstract]

Pterostilbene (Pte) (50 mg/kg; once daily; i.g.; 7 d) markedly improved survival rate of mice and alleviated clinical signs of EV-A71 infection.
J Agric Food Res

2026 May 30;29:103045.
J Agric Food Chem

Resveratrol Reactivates Latent HIV through Increasing Histone Acetylation and Activating Heat Shock Factor 1. [Abstract]

2017 Jun 7;65(22):4384-4394. PMID: 28471170
J Nutr Biochem

Comparative study of lipophilicity, cell membrane permeability, and intracellular antioxidant capacity of resveratrol and pterostilbene. [Abstract]

2025 Sep 5:147:110095. PMID: 40915507
Arch Biochem Biophys

Pterostilbene ameliorates oxidative damage and ferroptosis in human ovarian granulosa cells by regulating the Nrf2/HO-1 pathway. [Abstract]

2023 Apr:738:109561. PMID: 36898621

Pterostilbene purchased from MedChemExpress. Usage Cited in: Arch Biochem Biophys. 2023 Apr:738:109561. [Abstract]

Pterostilbene (20 μM; 6 h) can reverse the changes of ferroptosis-related proteins in OGCs (COV434 and KGN cells) induced by H₂O₂. Pterostilbene significantly increases the expression of GPX4 while decreases the expression of ACSL4.
Immun Inflamm Dis

Pterostilbene suppresses oxidative stress and allergic airway inflammation through AMPK/Sirt1 and Nrf2/HO-1 pathways. [Abstract]

2021 Dec;9(4):1406-1417. PMID: 34342160
J Pharmacol Sci

Pterostilbene alleviates liver ischemia/reperfusion injury via PINK1-mediated mitophagy. [Abstract]

2022 Jan;148(1):19-30. PMID: 34924126
J Nat Med

Xanthohumol attenuates TXNIP-mediated renal tubular injury in vitro and in vivo diabetic models. [Abstract]

2025 Mar;79(2):314-327. PMID: 39752106

Solvant et solubilité

In Vitro:

DMSO : 110 mg/mL (429.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9017 mL

19.5084 mL

39.0168 mL

5 mM

0.7803 mL

3.9017 mL

7.8034 mL

10 mM

0.3902 mL

1.9508 mL

3.9017 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 3.93 mg/mL (15.33 mM); Clear solution

This protocol yields a clear solution of ≥ 3.93 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (39.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.75 mg/mL (10.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.75 mg/mL (10.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 15% Cremophor EL 85% Saline

Solubility: 3.33 mg/mL (12.99 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (273 KB)
SDS (620 KB)
- English - EN (620 KB)
- Français - FR (620 KB)
- Deutsch - DE (620 KB)
- Norwegian - NO (620 KB)
- Español - ES (620 KB)
- Swedish - SV (620 KB)
- Italian - IT (620 KB)
- Korean - KR (620 KB)
- Portuguese - PT (620 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. McCormack D, et al. A review of pterostilbene antioxidant activity and disease modification. Oxid Med Cell Longev. 2013;2013:575482. [Content Brief]

[2]. Hong Bin W, et al. Pterostilbene (3',5'-dimethoxy-resveratrol) exerts potent antitumor effects in HeLa human cervical cancer cells via disruption of mitochondrial membrane potential, apoptosis induction and targeting m-TOR/PI3K/Akt signalling pathway. J BUON. 2018 Sep-Oct;23(5):1384-1389. [Content Brief]

[3]. Perecko T, et al. The effects of pterostilbene on neutrophil activity in experimental model of arthritis. Biomed Res Int. 2013;2013:106041. [Content Brief]

[4]. Acharya JD, et al. Protective effect of Pterostilbene against free radical mediated oxidative damage. BMC Complement Altern Med. 2013 Sep 26;13:238. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.9017 mL	19.5084 mL	39.0168 mL	97.5419 mL
	5 mM	0.7803 mL	3.9017 mL	7.8034 mL	19.5084 mL
	10 mM	0.3902 mL	1.9508 mL	3.9017 mL	9.7542 mL
	15 mM	0.2601 mL	1.3006 mL	2.6011 mL	6.5028 mL
	20 mM	0.1951 mL	0.9754 mL	1.9508 mL	4.8771 mL
	25 mM	0.1561 mL	0.7803 mL	1.5607 mL	3.9017 mL
	30 mM	0.1301 mL	0.6503 mL	1.3006 mL	3.2514 mL
	40 mM	0.0975 mL	0.4877 mL	0.9754 mL	2.4385 mL
	50 mM	0.0780 mL	0.3902 mL	0.7803 mL	1.9508 mL
	60 mM	0.0650 mL	0.3251 mL	0.6503 mL	1.6257 mL
	80 mM	0.0488 mL	0.2439 mL	0.4877 mL	1.2193 mL
	100 mM	0.0390 mL	0.1951 mL	0.3902 mL	0.9754 mL

Keywords

Pterostilbene

11 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Pterostilbene

Immunology/Inflammation Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Lipid Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

Anti-Obesity Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Pterostilbene

Activité biologique

Chemical Information

Publications (11)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Pterostilbene Related Classifications

HY-N0828 Related Classifications